Request Demo
Last update 31 May 2025
TAK-058
Last update 31 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms ENV-8058, TAK 058 |
Target |
Action antagonists |
Mechanism 5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with TAK-058NCT02614586
A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of TAK-058 and Ondansetron on P50 Auditory Gating in Subjects With Stable Schizophrenia
NCT02389881
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058
NCT02153099
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects
100 Clinical Results associated with TAK-058
Login to view more data
100 Translational Medicine associated with TAK-058
Login to view more data
100 Patents (Medical) associated with TAK-058
Login to view more data
100 Deals associated with TAK-058
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Schizophrenia | Phase 1 | United States | 01 Feb 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 40 | (Cohort 1 Non-elderly Healthy: TAK-058 25 mg) | qmikulwvlw = dnhynsovlq aqvfwuvaol (ymbytqtckf, eamsljiozb - griyqayijc) View more | - | 23 Feb 2017 | ||
(Cohort 2 Non-elderly Healthy: TAK-058 75 mg) | qmikulwvlw = fydsltbydd aqvfwuvaol (ymbytqtckf, vmjjxapmfh - xswdwuecwn) View more | ||||||
Phase 1 | - | 48 | (Cohort 4: TAK-058 5 mg) | dsgigytrvp = wxscgqsaul iogqdwuyro (yfueravtck, apajsidkww - kdfkdfvilt) View more | - | 17 Dec 2015 | |
(Cohort 1: TAK-058 15 mg) | dsgigytrvp = aofbxhwnbg iogqdwuyro (yfueravtck, vedpduqjkf - amcsjuquxk) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free